rate reports, entitled "Instruction Manual for Electronic Filing of the Index of Customers," and "Instruction Manual for Electronic Filing of the Discount Transportation Rate Report," respectively, and attached to this notice as Appendices A and B, are hereby adopted. The first electronic filing of the Index of Customers under sections 284.106(c) and 284.223(b) will be April 1, 1996. April 1 is one of the four scheduled filing dates provided for in the referenced regulations. The first discount rate reports to be filed electronically will be the reports due for the month of March 1996. Those reports are due within 15 days of the close of the March billing period.

By direction of the Commission. Lois D. Cashell, *Secretary.* [FR Doc. 96–5166 Filed 3–5–96; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, and 524

Animal Drugs, Feeds, and Related Products; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for 28 approved new animal drug applications (NADA's) from Coopers Animal Health, Inc., to Mallinckrodt Veterinary, Inc.

EFFECTIVE DATE: March 6, 1996.

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: Coopers Animal Health, Inc., 1201 Douglas Ave., Kansas City, KS 66103–1438, has informed FDA that it has transferred the ownership of, and all rights and interests in, the following approved NADA's to Mallinckrodt Veterinary, Inc., Mundelein, IL 60060.

NADA No.	Trade name	Active ingredi- ent	NADA No.	Trade name	Active ingredi ent
6–602	A–H Tablets 25 milli-	Doxylamine Succinate	106–965	Tribrissen 48% Injec- tion.	Trimethoprim Sulfadiazin
	grams (mg)/ 100 mg.		116–087	Burazolidin	Phenylbutazo
6–983	A-H Injection	Doxylamine Succinate, Chlorobuta-		Paste/ Butazolidin/ Phenylzone/	ne
10–987	Butazolidin Tablets/	nol Phenylbutazo- ne	120–326	Bute. Filban Chewable	Diethylcarba- mazine Cit
11–222	Bolus. Diquel Tablets	Ethylisobutra- zine Hydro-	124–842	Wafers. Filban Tablets	rate Diethylcarba- mazine Cit rate
11–575	Butazolidin In- jection 20%.	chloride Phenylbutazo- ne	131–918	Tribrissen 400 Oral Paste.	Trimethoprim Sulfadiazin
11–877	Jenotone Tab- lets.	Aminopromaz- ine Fumarate	136–741	Tribrissen 60 Oral Sus- pension.	Trimethoprim Sulfadiazin
11–893	Dermathycin Injection.	Thyroid Stim- ulating Hor-	The agency is amending 21 CFR 510.600(c)(1) and (c)(2), and parts 520,		
15–182	Canopar Tab- lets.	mone Thenium Closylate	522, and 524 to reflect the change of sponsor.		
13–181	Jenomycin Tablets.	Aminopromaz- ine	List of Subjects		
		Fumarate, Neomycin	21 CFR Part 510		
34–477	Jenotone So-	Sulfate Aminopromaz-	Administrative practice and procedure, Animal drugs, Labeling,		
	lution.	ine Fumarate	Reporting and recordkeeping requirements.		
35–016	Scolaban 400	Bunamidine Hydro-	21 CFR Parts 520, 522, and 524		
35–265	Diquel Solu- tion.	chloride Ethylisobutra- zine Hydro- chloride	Animal drugs. Therefore, under the Federal Food, Drug, and Cosmetic Act and under		
38–800	Butazolidin Granules.	Phenylbutazo- ne	authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21		
44–757 48–913	Prolate I–E Halox Wormer Drench.	Phosmet Haloxon	CFR parts 510, 520, 522, and 524 are amended as follows:		
65–476	Cortisporin Veterinary	Bactricin ZN, Neomycin	PART 510—NEW ANIMAL DRUGS		
	Ophthalmic Ointment.	Sulfate, Polymyxin B Sulfate,	1. The authority citation for 21 CF part 510 continues to read as follows		
		Hydro- cortisone Acetate	512, 701, 721	Secs. 201, 301, 50 of the Federal Fo	ood, Drug, and
65–485	Neosporin Ophthalmic	Bactricin ZN, Neomycin	Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).		
	Ointment.	Sulfate, Polymyxin B Sulfate		510.600 is amo	
92–483	Halox Bolus	Haloxon	table in para	graph (c)(1) by ''Coopers Anii	removing mal Health
95–614	Tribrissen 30/ 120/480/ 960 Tablets.	Sulfadiazine, Trimethopri- m	Inc.''; and in	the table in pa	iragraph
97–288	Imizol Equine Injection.	Imidocarb Dipropionat-	"017220".	ORAL DOSAG	
101–161	Thenatol PW Tablets.	e Thenium Closylate,	NEW ANIMA	L DRUGS	
		Piperazine Phosphate	part 520 con	hority citation tinues to read	as follows:
105–093	Tribrissen 24% Injec- tion.	Trimethoprim, Sulfadiazine Sodium		Sec. 512 of the Fe smetic Act (21 U.	

§520.82a [Amended]

4. Section 520.82a *Aminopropazine fumarate tablets* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.82b [Amended]

5. Section 520.82b *Aminopropazine fumarate, neomycin sulfate tablets* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.222 [Amended]

6. Section 520.222 *Bunamidine hydrochloride* is amended in paragraph (c) by removing "017220" and adding in its place "011716".

§520.622c [Amended]

7. Section 520.622c

Diethylcarbamazine citrate chewable tablets is amended in paragraph (b)(5) by removing "017220" and adding in its place "011716".

§520.784 [Amended]

8. Section 520.784 *Doxylamine* succinate tablets is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§ 520.863 [Amended]

9. Section 520.863 *Ethylisobutrazine hydrochloride tablets* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§ 520.1120a [Amended]

10. Section 520.1120a *Haloxon drench* is amended in paragraph (c) by removing "017220" and adding in its place "011716".

§520.1120b [Amended]

11. Section 520.1120b *Haloxon boluses* is amended in paragraph (c) by removing "017220" and adding in its place "011716".

§520.1720a [Amended]

12. Section 520.1720a *Phenylbutazone tablets and boluses* is amended in paragraph (b)(1) by removing "017220" and adding in its place "011716".

§520.1720b [Amended]

13. Section 520.1720b *Phenylbutazone granules* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.1720c [Amended]

14. Section 520.1720c *Phenylbutazone paste* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.1805 [Amended]

15. Section 520.1805 *Piperazine phosphate with thenium closylate tablets* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.2362 [Amended]

16. Section 520.2362 *Thenium closylate tablets* is amended in paragraph (c) by removing "017220" and adding in its place "011716".

§520.2610 [Amended]

17. Section 520.2610 *Trimethoprim and sulfadiazine tablets* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.2611 [Amended]

18. Section 520.2611 *Trimethoprim and sulfadiazine oral paste* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§520.2612 [Amended]

19. Section 520.2612 *Trimethoprim and sulfadiazine oral suspension* is amended in paragraph (b) by removing ''017220'' and adding in its place ''011716''.

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

20. The authority citation for 21 CFR Part 522 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§522.82 [Amended]

21. Section 522.82 *Aminopropazine fumarate sterile solution injection* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§522.784 [Amended]

22. Section 522.784 *Doxylamine succinate injection* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§522.863 [Amended]

23. Section 522.863 *Ethylisobutrazine hydrochloride injection* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§522.1155 [Amended]

24. Section 522.1155 *Imidocarb dipropionate sterile powder* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

§522.1720 [Amended]

25. Section 522.1720 *Phenylbutazone injection* is amended in paragraph (b)(1) by removing "017220" and adding in its place "011716".

§522.2610 [Amended]

26. Section 522.2610 *Trimethoprim and sulfadiazine sterile suspension* is amended in paragraphs (a)(2) and (b)(2) by removing "017220" and adding in its place "011716".

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

27. The authority citation for 21 CFR part 524 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§524.154 [Amended]

28. Section 524.154 *Bacitracin or bacitracin zinc-neomycin sulfate-polymyxin B sulfate ophthalmic ointment* is amended in paragraph (a)(2) by removing "017220" and adding in its place "011716".

§524.155 [Amended]

29. Section 524.155 Bacitracin zincpolymyxin B sulfate neomycin sulfatehydrocortisone or hydrocortisone acetate ophthalmic ointment is amended in paragraph (a)(1) by removing "017220" and adding in its place "011716".

§524.1742 [Amended]

30. Section 524.1742 *N*-(*Mercaptomethyl*) *phthalimide S-(O,Odimethyl phosphorodithioate*) *emulsifiable liquid* is amended in paragraph (b) by removing "017220" and adding in its place "011716".

Dated: February 28, 1996.

Robert C. Livingston, Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 96–5213 Filed 3–5–96; 8:45 am] BILLING CODE 4160–01–F

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[KY-71-2-6062a; FRL-5427-4]

Approval and Promulgation of Implementation Plans—Kentucky: Approval of Revision To The State Implementation Plan

AGENCY: Environmental Protection Agency (EPA). **ACTION:** Direct final rule.

SUMMARY: This action approves a revision to the Kentucky State Implementation Plan (SIP) adopted by the Kentucky Natural Resources and Environmental Protection Cabinet

(KNREP) on March 4, 1993, for the